Table S6.

Bucher indirect meta-analysis of American College of Rheumatology (ACR) criteria scores of 20, 50, and 70 outcomes: licensed DMARD monotherapy in DMARD-experienced patients

Treatment	Control	Fixed effect		Random effects
		OR v control (95% CI)	P-value	OR v control (95% CI)	P-value
ACR 20
ETN 2 25 mg/week	ADA 40 mg/2 weeks	2.148 (0.818, 5.639)	0.121	2.14 (0.816, 5.616)	0.122
ETN 2 25 mg/week	TOC 8 mg/kg/4 weeks	0.404 (0.105, 1.555)	0.187	0.404 (0.105, 1.555)	0.187
ACR 50
ETN 2 25 mg/week	ADA 40 mg/2 weeks	2.705 (0.749, 9.774)	0.129	2.731 (0.756, 9.872)	0.125
ETN 2 25 mg/week	TOC 8 mg/kg/4 weeks	0.361 (0.035, 3.71)	0.392	0.361 (0.035, 3.71)	0.392
ACR 70
ETN 2 25 mg/week	ADA 40 mg/2 weeks	2.368 (0.207, 27.089)	0.488	2.539 (0.222, 29.066)	0.454
ETN 2 25 mg/week	TOC 8 mg/kg/4 weeks	0.632 (0.018, 22.108)	0.800	0.632 (0.018, 22.108)	0.800

Notes: SUL not connected to placebo, so no direct results; P < 0.05 is statistically significant.

Abbreviations: ADA, adalimumab; CI, confidence interval; DMARD, disease-modifying antirheumatic drug; ETN, etanercept; OR, odds ratio; SUL, sulfasalazine; TOC, tocilizumab.